scholarly journals Case of Six-Year Disease-Free Survival with Undifferentiated Carcinoma of the Pancreas

2016 ◽  
Vol 10 (2) ◽  
pp. 472-478 ◽  
Author(s):  
Hiroyuki Saito ◽  
Hiroshi Kashiyama ◽  
Takashi Murohashi ◽  
Kazunari Sasaki ◽  
Ryosuke Misawa ◽  
...  
Keyword(s):  
Mixed Type ◽  
Disease Free Survival ◽  
Giant Cells ◽  
Undifferentiated Carcinoma ◽  
Maintenance Chemotherapy ◽  
Free Survival ◽  
Carcinoma Of The Pancreas ◽  
Dismal Prognosis ◽  
Diaphragmatic Invasion ◽  
Disease Free

Undifferentiated carcinoma of the pancreas (UDC) is rare and has a dismal prognosis. Here, we report a case of 6-year disease-free survival with a mixed type of UDC and UDC with osteoclast-like giant cells, with a high mitotic index as well as perineural, lymphatic, vessel, and diaphragmatic invasion. The patient underwent radical distal pancreatectomy and was subsequently treated with adjuvant chemotherapy using gemcitabine plus S-1 followed by maintenance chemotherapy with oral tegafur-uracil. The patient has been doing well with no evidence of recurrence for more than 6 years after surgery.

scholarly journals EPEN-49. RESPONSE OF RECURRENT EPENDYMOMA TO MEMMAT BASED METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY UTILIZING TAPERED BEVACIZUMAB AND MAINTENANCE THERAPY WITH CELECOXIB AND FENOFIBRATE

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii317-iii317
Author(s):  
Eileen Gillan
Keyword(s):  
Combination Therapy ◽  
Maintenance Therapy ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Time To Progression ◽  
Free Survival ◽  
Dismal Prognosis ◽  
Recurrent Ependymoma ◽  
Disease Free

Abstract Recurrent ependymomas have a dismal prognosis (2 year survival rates 29% OS and 23% EFS) and are relatively resistant to conventional chemotherapy. We previously reported five relapsed ependymoma patients treated with a MEMMAT based metronomic antiangiogenic combination therapy. All patients are currently alive, including four patients who were multiply relapsed with at least three recurrences. These four patients received between 44–52 weeks of therapy with minimal toxicity. Three had recurrent disease within an average of 44 months (median 42 months) after discontinuation of therapy. One patient who received the following tapering bevacizumab schedule: q3 weeks x 3, q4 weeks x 4 and q5 weeks x 5 followed by maintenance therapy with fenofibrate and celecoxib is in complete remission 12 months post treatment. This regimen was well tolerated with good quality of life in this patient population. Our results suggest that the chosen anti-angiogenic drug combination prolonged the time to progression in these multiply relapsed patients and thus may be particularly beneficial for patients with recurrent ependymoma. Tapered bevacizumab and maintenance therapy with celecoxib and fenofibrate may be modifications worth further investigation for prolonged disease free survival in relapsed ependymoma patients.

scholarly journals Long-term disease-free survival in acute nonlymphocytic leukemia

Blood ◽  
1981 ◽  
Vol 57 (6) ◽  
pp. 1144-1147
Author(s):  
BA Peterson ◽  
CD Bloomfield
Keyword(s):  
Complete Remission ◽  
Induction Chemotherapy ◽  
Median Survival ◽  
Cytosine Arabinoside ◽  
Disease Free Survival ◽  
Acute Nonlymphocytic Leukemia ◽  
Maintenance Chemotherapy ◽  
Free Survival ◽  
Disease Free

Twenty-six of 45 adults (58%) with acute nonlymphocytic leukemia who were treated with intensive induction chemotherapy over 5 yr ago entered complete remission. All patients entering remission were placed on weekly maintenance chemotherapy consisting of cytosine arabinoside and 6-thioguanine. The median duration of complete remission was 17 mo and 7 patients (27%) remained in their initial remission for 62 + to 102 + mo. All but one of the patients in complete remission over 5 yr have had treatment discontinued. Only 1 of 7 patients in remission for more than 5 yr has relapsed. Median survival is 26.5 mo, and 8 patients (31%) currently remain alive without evidence of leukemia 63--105 mo from diagnosis. It is possible to achieve long-term disease-free survival with chemotherapy alone in acute nonlymphocytic leukemia.

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study

Blood ◽  
2007 ◽  
Vol 110 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Norio Asou ◽  
Yuji Kishimoto ◽  
Hitoshi Kiyoi ◽  
Masaya Okada ◽  
Yasukazu Kawai ◽  
...  
Keyword(s):  
Complete Remission ◽  
Acute Promyelocytic Leukemia ◽  
Randomized Study ◽  
Disease Free Survival ◽  
Promyelocytic Leukemia ◽  
Consolidation Therapy ◽  
Maintenance Chemotherapy ◽  
Free Survival ◽  
Significant Difference ◽  
Disease Free

To examine the efficacy of intensified maintenance chemotherapy, we conducted a prospective multicenter trial in adult patients with newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Of the 302 registered, 283 patients were assessable and 267 (94%) achieved complete remission. Predicted 6-year overall survival in all assessable patients and disease-free survival in patients who achieved complete remission were 83.9% and 68.5%, respectively. A total of 175 patients negative for PML-RARα at the end of consolidation were randomly assigned to receive either intensified maintenance chemotherapy (n = 89) or observation (n = 86). Predicted 6-year disease-free survival was 79.8% for the observation group and 63.1% for the chemotherapy group, showing no statistically significant difference between the 2 groups (P = .20). Predicted 6-year survival of patients assigned to the observation was 98.8%, which was significantly higher than 86.2% in those allocated to the intensified maintenance (P = .014). These results indicate that the intensified maintenance chemotherapy did not improve disease-free survival, but rather conferred a significantly poorer chance of survival in acute promyelocytic leukemia patients who have become negative for the PML-RARα fusion transcript after 3 courses of intensive consolidation therapy.

Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.

1986 ◽  
Vol 4 (5) ◽  
pp. 710-715 ◽  
Author(s):  
E C Holmes ◽  
M Gail
Keyword(s):  
Weight Loss ◽  
Disease Free Survival ◽  
Large Cell ◽  
Undifferentiated Carcinoma ◽  
Stage Ii ◽  
Free Survival ◽  
Lung Cancer Study Group ◽  
Resected Stage ◽  
To Receive ◽  
Disease Free

The Lung Cancer Study Group randomized 141 patients with resected stage II and III adenocarcinoma and large-cell undifferentiated carcinoma to receive postoperative Cytoxan (Bristol-Meyers, Syracuse, NY), Adriamycin (Adria Laboratories, Columbus, Ohio), and cisplatin (CAP) chemotherapy or bacillus Calmette-Guerin (BCG) and levamisole immunotherapy. Careful intraoperative staging was performed on all patients. Before randomization, patients were stratified by stage, weight loss, cardiac arrhythmia, and institution. Prognostic variables such as stage, age, weight loss, and nodal involvement were equally distributed between the two groups. Disease-free survival was significantly prolonged in the group receiving chemotherapy. There was no evidence of a deleterious effect of the immunotherapy. This study indicates that postoperative CAP chemotherapy is effective in prolonging disease-free survival in these patients.

Induction chemotherapy followed by concurrent chemotherapy and proton beam for sinonasal undifferentiated carcinoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17557-e17557
Author(s):  
Yue Christine Lu ◽  
Judith A. Adams ◽  
John Ross Clark ◽  
Norbert Liebsch ◽  
Annie W Chan
Keyword(s):  
Proton Beam ◽  
Induction Chemotherapy ◽  
Concurrent Chemoradiotherapy ◽  
Disease Free Survival ◽  
Undifferentiated Carcinoma ◽  
Concurrent Chemotherapy ◽  
Primary Site ◽  
Free Survival ◽  
Sequential Group ◽  
Disease Free

e17557 Background: The optimal treatment of sinonasal undifferentiated carcinoma (SNUC) remains to be defined given its aggressiveness and dismal outcome with traditional treatment. We examined the treatment outcomes of SNUC treated with combined proton beam with concurrent chemotherapy +/- induction chemotherapy. Methods: Between 2005 and 2016, 15 patients with SNUC were treated at our institution. All patients had T4 disease, with 20% had nodal involvement and 87% with orbital invasion. Forty-seven percent of patients underwent induction chemotherapy followed by concurrent chemoradiotherapy (sequential group) and 53% underwent or concurrent chemoradiotherapy alone. All patients underwent proton beam for the primary site and upper neck, and photon irradiation for the lower neck. The median dose to the primary site was 70Gy(RBE). Locoreigonal control, freedom from distant metastasis, disease-free survival, and overall survival were estimated by the Kaplan-Meier method. Results: With a median follow-up of 25 months, there were 2 local, 2 regional, 4 distant, and 5 dural-leptomeningeal failures. The 2-year locoregional control rates were 100% and 60% (95%CI:33%-100%) for the sequential and concurrent alone groups, respectively, (p=0.10). The 2-year overall survival was 100% for the sequential group and 58% (95%CI:31%-100%) for the concurrent group (p=0.03). The 2-year distant-metastasis-free survival was 83% (95%CI:58%-100%) and 31% (95%CI:10%-96%) for the sequential and concurrent group, respectively (p= 0.03). Furthermore, the sequential group has a 2-year disease-free survival rate of 100% compared with 58% (95%CI:31%-100%) for the concurrent group (p=0.02). Conclusions: Induction chemotherapy followed by concurrent chemotherapy and proton beam results in promising outcome in patients with SNUC.

A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.

1983 ◽  
Vol 1 (2) ◽  
pp. 138-145 ◽  
Author(s):  
D C Tormey ◽  
V E Weinberg ◽  
J F Holland ◽  
R B Weiss ◽  
O J Glidewell ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Maintenance Chemotherapy ◽  
Free Survival ◽  
Premenopausal Patients ◽  
To Receive ◽  
Disease Free ◽  
Positive Breast Cancer

Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients). After 5 yr of accrual and a median follow-up of 34 mo, CMFVP is superior to CMF (p less than 0.01) with disease-free survival estimates at 4 yr of 60% for CMFVP compared to 45% for CMF. The disease-free survival advantage of CMFVP over CMF was greater in postmenopausal (p = 0.02) than in premenopausal patients (p = 0.09). CMF-MER was similar to CMF alone. CMF related side effects were similar in each regimen (see text), except for a greater incidence of leukopenia during induction with CMF than with CMFVP (p less than 0.01).

scholarly journals Long-term disease-free survival in acute nonlymphocytic leukemia

Blood ◽  
1981 ◽  
Vol 57 (6) ◽  
pp. 1144-1147 ◽  
Author(s):  
BA Peterson ◽  
CD Bloomfield
Keyword(s):  
Complete Remission ◽  
Induction Chemotherapy ◽  
Median Survival ◽  
Cytosine Arabinoside ◽  
Disease Free Survival ◽  
Acute Nonlymphocytic Leukemia ◽  
Maintenance Chemotherapy ◽  
Free Survival ◽  
Disease Free

Abstract Twenty-six of 45 adults (58%) with acute nonlymphocytic leukemia who were treated with intensive induction chemotherapy over 5 yr ago entered complete remission. All patients entering remission were placed on weekly maintenance chemotherapy consisting of cytosine arabinoside and 6-thioguanine. The median duration of complete remission was 17 mo and 7 patients (27%) remained in their initial remission for 62 + to 102 + mo. All but one of the patients in complete remission over 5 yr have had treatment discontinued. Only 1 of 7 patients in remission for more than 5 yr has relapsed. Median survival is 26.5 mo, and 8 patients (31%) currently remain alive without evidence of leukemia 63--105 mo from diagnosis. It is possible to achieve long-term disease-free survival with chemotherapy alone in acute nonlymphocytic leukemia.

Aggressive combined modality therapy for advanced local-regional breast carcinoma.

1984 ◽  
Vol 2 (3) ◽  
pp. 157-163 ◽  
Author(s):  
C L Loprinzi ◽  
P P Carbone ◽  
D C Tormey ◽  
P R Rosenbaum ◽  
W Caldwell ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Combined Modality Therapy ◽  
Disease Free Survival ◽  
Maintenance Chemotherapy ◽  
Time To Progression ◽  
Free Survival ◽  
Left Chest ◽  
Initial Surgery ◽  
Chest Irradiation ◽  
Disease Free

Thirty-two women with advanced local regional breast carcinoma, including nine patients with histologically diagnosed inflammatory cancer, were entered on a prospective pilot study. They were treated aggressively with initial surgery, two courses of induction chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil, +/- prednisone, +/- tamoxifen (CMF [P] [T]), local-regional radiotherapy, and then maintenance chemotherapy with CMF(P) (T) alternating with doxorubicin, vincristine, +/- tamoxifen (AV[T]). The patients have been followed for 19-70 months from the time of mastectomy and their actuarial three-year survival is 65% with a median survival that has not yet been reached. Median disease-free survival (time to progression) is currently 29.5 months. Women whose gross disease could not be totally resected surgically had shorter disease-free survivals than those rendered surgically free of disease (p = 0.01). Clinically evident cardiotoxicity was seen in 25% of the patients and was felt to be primarily due to the combination of doxorubicin and radiation therapy. It was significantly more common (Plt less than 0.05) in patients with left chest irradiation (seven of 18 women) as opposed to those with right-sided irradiation (one of 14).

Prolonged Disease-Free Survival by Maintenance Chemotherapy among Patients with Recurrent Platinum-Sensitive Ovarian Cancer

1998 ◽  
Vol 71 (2) ◽  
pp. 190-195 ◽  
Author(s):  
Gamal H. Eltabbakh ◽  
M.Steven Piver ◽  
Ronald E. Hempling ◽  
Fernando O. Recio ◽  
Leslie E. Blumenson
Keyword(s):  
Ovarian Cancer ◽  
Disease Free Survival ◽  
Maintenance Chemotherapy ◽  
Free Survival ◽  
Platinum Sensitive ◽  
Disease Free
Sign in / Sign up

Export Citation Format

Share Document